Literature DB >> 11272693

The spectrum of acute bronchitis. Using baseline factors to guide empirical therapy.

K R Flaherty1, S Saint, A M Fendrick, F J Martinez.   

Abstract

The optimal therapy for acute bronchitis depends on the causative pathogen and the presence or absence of underlying lung disease. Because there is no fast, reliable way to identify the pathogen, physicians have to rely on clinical judgment and epidemiologic characteristics. In this article, Drs Flaherty, Saint, Fendrick, and Martinez discuss how an evidence-based approach to treatment may help ensure that efficacious therapy is available in the future.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11272693     DOI: 10.3810/pgm.2001.02.859

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  4 in total

1. 

Authors:  J E Losa García; M R Martín de Cabo
Journal:  Medicine (Madr)       Date:  2013-04-03

Review 2.  Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis.

Authors:  Cristian Jivcu; Mark Gotfried
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-08-03

3.  Efficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis.

Authors:  W Kamin; V G Maydannik; F A Malek; M Kieser
Journal:  Acta Paediatr       Date:  2010-01-11       Impact factor: 2.299

Review 4.  Acute bronchitis: state of the art diagnosis and therapy.

Authors:  Fernando J Martinez
Journal:  Compr Ther       Date:  2004
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.